Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 4 (2007), Issue 12 (December)

1. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.
   Am J Obstet Gynecol, 197(6): 676.e1-7. [Abstract] [Full-text]
2. The association of tea consumption with ovarian cancer risk: A metaanalysis.
   Am J Obstet Gynecol, 197(6): 594.e1-6. [Abstract] [Full-text]
3. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
   Int J Cancer, 122(3): 534-46. [Abstract] [Full-text]
4. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer.
   Int J Cancer, 122(3): 647-52. [Abstract] [Full-text]
5. Nutrient dietary patterns and the risk of breast and ovarian cancers.
   Int J Cancer, 122(3): 609-13. [Abstract] [Full-text]
6. Improvement in the outcome of children with germ cell tumors.
   Pediatr Blood Cancer, 50(2): 250-3. [Abstract] [Full-text]
7. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
   Cancer Res, 67(24): 11933-41. [Abstract] [Full-text]
8. Oncogenic BARD1 isoforms expressed in gynecological cancers.
   Cancer Res, 67(24): 11876-85. [Abstract] [Full-text]
9. Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases.
   Am J Clin Pathol, 129(1): 110-4. [Abstract] [Full-text]
10. Role of triptolide as an adjunct chemotherapy for ovarian cancer.
    Chemotherapy, 54(1): 67-76. [Abstract] [Full-text]
11. Development of antiangiogenic agents for ovarian cancer.
    Expert Rev Anticancer Ther, 8(1): 21-32. [Abstract] [Full-text]
12. Recurrent ovarian granulosa cell tumors: clinical and imaging features.
    Abdom Imaging, 33(1): 119-25. [Abstract] [Full-text]
13. PET-CT vs. CT alone in ovarian cancer recurrence.
    Abdom Imaging, 33(1): 112-8. [Abstract] [Full-text]
14. Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes.
    Mol Carcinog, 47(1): 56-65. [Abstract] [Full-text]
15. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.
    Gynecol Oncol, 108(1): 34-41. [Abstract] [Full-text]
16. Declining trends of epithelial ovarian cancer in California.
    Gynecol Oncol, 108(1): 207-13. [Abstract] [Full-text]
17. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
    Gynecol Oncol, 108(1): 182-90. [Abstract] [Full-text]
18. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt.
    Gynecol Oncol, 108(1): 248-50. [Abstract] [Full-text]
19. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
    Gynecol Oncol, 108(1): 160-5. [Abstract] [Full-text]
20. Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis.
    Gynecol Oncol, 108(1): 173-81. [Abstract] [Full-text]
21. Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.
    Gynecol Oncol, 108(1): 191-4. [Abstract] [Full-text]
22. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
    Gynecol Oncol, 108(1): 166-72. [Abstract] [Full-text]
23. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
    Gynecol Oncol, 108(1): 90-4. [Abstract] [Full-text]
24. Factors associated with the suboptimal treatment of women less than 55 years of age with early-stage ovarian cancer.
    Gynecol Oncol, 108(1): 95-9. [Abstract] [Full-text]
25. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Gynecol Oncol, 108(1): 136-40. [Abstract] [Full-text]
26. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.
    Gynecol Oncol, 108(1): 100-5. [Abstract] [Full-text]
27. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Gynecol Oncol, 108(1): 47-52. [Abstract] [Full-text]
28. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
    Gynecol Oncol, 108(1): 68-71. [Abstract] [Full-text]
29. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Gynecol Oncol, 108(1): 53-7. [Abstract] [Full-text]
30. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
    J Clin Oncol, 26(1): 76-82. [Abstract] [Full-text]
31. BRCA1 p.Val1688del is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast Italy.
    J Clin Oncol, 26(1): 26-31. [Abstract] [Full-text]
32. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    J Clin Oncol, 26(1): 20-5. [Abstract] [Full-text]
33. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol, 26(1): 83-9. [Abstract] [Full-text]
34. Ovarian thecoma: clinicopathological analysis of 50 cases.
    Ann Diagn Pathol, 12(1): 12-6. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.